Abstracts tagged "corticosteroids"

Abstract Number: 2778 • 2014 ACR/ARHP Annual Meeting
Non-Systemic Vasculitic Neuropathy: Presentation, Therapeutic Management and Outcome
Benjamin Terrier¹, Fleur Cohen², Aude Rigolet³, Jean-Emmanuel Kahn⁴, Alice Berezne⁵, Olivier Benveniste⁶, Alain Créange⁷, Thierry Maisonobe⁸, Zahir Amoura⁹, Luc Mouthon¹⁰ and Loïc Guillevin for the French Vasculitis Study Group¹⁰, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²Internal Medicine, Pitié-Salpétrière, Paris, France, ³Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, ⁴Internal Medicine, Foch Hospital, Suresnes, France, ⁵Paris Descartes University, Internal Medicine department, Cochin Hospital, Paris, France, ⁶UMR 974, Sorbonne Universités, University Pierre et Marie-Curie-Paris 6, INSERM, Paris, France, ⁷Neurology, Henri Mondor, Créteil, France, ⁸Neuropathology, Pitie-Salpetriere Hospital, Paris, France, ⁹Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ¹⁰National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France
Background/Purpose Non-systemic vasculitic neuropathy (NSVN) is a small-to-medium–sized vessel vasculitis limited to the peripheral nervous system. It can be considered a single-organ vasculitis, as recently…
Abstract Number: 1857 • 2014 ACR/ARHP Annual Meeting
Determinants of Annual Healthcare Utilization and Overall Cost of Care in Individuals with Systemic Lupus Erythematosus in a Large Insurance Claims Database: Glucocorticoid Use
Shih-Yin Chen¹, Chan-Bum Choi^2,3,4, Qian Li⁵, Wei-Shi Yeh¹, Yuan-Chi Lee⁶, Amy H Kao¹ and Matthew H. Liang⁷, ¹Biogen Idec, Cambridge, MA, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Section of Rheumatology, VA Healthcare System, Boston, MA, ⁴Department of Aging, Brigham and Women's Hospital, Boston, MA, ⁵Evidera, Lexington, MA, ⁶Formerly of Evidera, Lexington, MA, ⁷Harvard Medical School, Boston, MA
Background/Purpose: Newer therapeutic agents in systemic lupus erythematosus (SLE) may increase cost of care but their effect on limiting the duration and the dosage of…
Abstract Number: 1397 • 2014 ACR/ARHP Annual Meeting
Impact of Corticosteroid Use on Remission Sustainability and Infection Rates Among Rheumatoid Arthritis Patients in Remission While on Infliximab: Treatment Implications Based on a Real-World Canadian Population
Boulos Haraoui¹, Algis Jovaisas², William G. Bensen³, Rafat Faraawi⁴, John Kelsall⁵, Sanjay Dixit⁴, Jude Rodrigues⁶, Maqbool Sheriff⁷, Emmanouil Rampakakis⁸, John S. Sampalis⁸, Allen J Lehman⁹, Susan Otawa⁹, Francois Nantel¹⁰ and May Shawi¹⁰, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Department of Medicine, Division of Rheumatology, St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁶Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada
Background/Purpose The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…
Abstract Number: 1252 • 2014 ACR/ARHP Annual Meeting
Intravenous Methylprednisolone Pulse Therapy in Severe Inflammatory Eye Disease. a Multicenter Study
Montserrat Santos-Gómez¹, Emma Beltrán², Vanesa Calvo-Río¹, Ricardo Blanco¹, Norberto Ortego³, Jose L. García Serrano⁴, Lucía Martínez Costa⁴, Alejandro Fonollosa⁵, Marisa Hernández⁶, Elia Valls⁷, Félix Francisco⁸, Miguel A. Reyes⁹, Ignacio Torre Salaberri¹⁰, Olga Maíz¹¹, Ana Blanco¹², Santiago Muñoz-Fernández¹³, M. Mar Esteban¹⁴, Esperanza Pato¹⁵, Manuel Díaz-Llopis¹⁶, Roberto Gallego¹⁶, Miguel Cordero¹⁷, Francisco Ortiz-Sanjuán¹, Joaquín Cañal Villanueva¹⁸, Leyre Riancho-Zarrabeitia¹ and Miguel A González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Rheumatology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ³Autoimmune Disease Unit, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ⁴Ophthalmology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ⁵Ophthalmology, Hospital de Cruces. Bilbao. Spain, Bilbao, Spain, ⁶Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ⁷Rheumatology, Hospital Dr. Peset. Valencia. Spain, Valencia, Spain, ⁸Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, ⁹Ophthalmology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, ¹⁰Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ¹¹Rheumatology, Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain, ¹²Ophthalmology, Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain, ¹³Rheumatology, Hospital Infanta Sofía. San Sebastián de los Reyes. Spain, Madrid, Spain, ¹⁴Ophthalmology, Hospital Infanta Sofía. San Sebastián de los Reyes. Spain, Madrid, Spain, ¹⁵Rheumatology, Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, ¹⁶Ophthalmology, Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ¹⁷Ophthalmology, Hospital de León. Spain, León, Spain, ¹⁸Ophthalmology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain
Intravenous methylprednisolone pulse therapy in severe inflammatory eye disease. A Multicenter Study.Background/Purpose Treatment with high-dose intravenous methylprednisolone (IVMP) pulse therapy has proved to be effective…
Abstract Number: 2318 • 2013 ACR/ARHP Annual Meeting
Disease Activity in Moderate and Severe Rheumatoid Arthritis At Discontinuation in 10-Year Open-Label Extension Studies With Etanercept
Michael E. Weinblatt¹, Joan M. Bathon², Michele Hooper³, Bojena Bitman⁴, Yue Yang⁵, David H. Collier⁶, James Chung⁷ and Mark C. Genovese⁸, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Amgen Global Safety, Amgen Inc., Thousand Oaks, CA, ⁴Amgen, Inc., San Francisco, CA, ⁵Assent Consulting, South San Francisco, CA, ⁶Amgen Inc., Thousand Oaks, CA, ⁷Amgen, Thousand Oaks, CA, ⁸Division of Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Retention rates may be used as a surrogate of long-term effectiveness of drug therapy in open-label studies. Studies have reported that patients (pts)…
Abstract Number: 1052 • 2013 ACR/ARHP Annual Meeting
Glucocorticosteroids and Mortality Risk In Rheumatoid Arthritis – Results Of a Population Based Study
Diane Lacaille¹, J. Antonio Avina-Zubieta^2,3, Eric C. Sayre², Michal Abrahamowicz⁴ and John Esdaile^1,5, ¹Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, ²Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁵Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Glucocorticosteroids (GC) are frequently used in the management of rheumatoid arthritis (RA). Due to their metabolic and immunosuppressive effects, they could increase the risk…
Abstract Number: 1007 • 2013 ACR/ARHP Annual Meeting
Dose Of Corticosteroid, Risk Of Adverse Events and Healthcare Resource Utilization In Systemic Lupus Erythematosus
Wei-Shi Yeh¹, Shih-Yin Chen², Kathleen McCarty³, Qian Li², Yuan-Chi Lee² and Nathalie Franchimont³, ¹Biogen Idec, Cambridge, MA, ²United BioSource Corporation, Lexington, MA, ³Biogen Idec Inc., Weston, MA
Background/Purpose: Gluco-corticosteroids (GCs) are frequently used to treat autoimmune disease and their chronic use has long been known to cause adverse events (AEs). The purpose…
Abstract Number: 2349 • 2012 ACR/ARHP Annual Meeting
Corticosterois Therapy Restaured Treg/Th17 Balance in Patients with Polimyalgia Rheumatica
Lorena Alvarez-Rodriguez¹, Marcos Lopez-Hoyos², Jaime Calvo-Alen³, Elena Aurrecoechea⁴, Teresa Ruiz Jimeno⁴, Ignacio Villa⁴, Carmen Gonzalez-Vela⁵ and Victor M. Martinez-Taboada¹, ¹Rheumatology, Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain, ²Immunology, Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain, ³Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁴Rheumatology, Hospital de Sierrallana, Torrelavega, Spain, ⁵Pathology Anatomy, Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain
Background/Purpose: To characterize the levels of circulating T regulatory cells (Tregs) and Th17 cells in polymyalgia rheumatica (PMR). Methods: The study included 46 patients with…
Abstract Number: 2241 • 2012 ACR/ARHP Annual Meeting
Efficacy of Belimumab in Systemic Lupus Erythematosus Patients with High Baseline Disease Activity
Ann E. Clarke¹, Susan Manzi², Michelle Petri³, Richard Furie⁴, Ronald F. van Vollenhoven⁵, Simon Cooper⁶, Z. John Zhong⁶, William W. Freimuth⁶ and Arthur Weinstein⁷, ¹Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ²Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴North Shore-LIJ Health System, Lake Success, NY, ⁵Karolinska University Hospital, Stockholm, Sweden, ⁶Human Genome Sciences, Inc., Rockville, MD, ⁷Washington Hospital Center, Washington, DC
Background/Purpose: To assess the efficacy of belimumab in patients with SLE who had high disease activity at baseline, as defined by SELENA-SLEDAI score ≥10. Methods: In…
Abstract Number: 1647 • 2012 ACR/ARHP Annual Meeting
Critical Management Decisions in Cardiac Neonatal Lupus: The Role of Fluorinated Steroids
Peter M. Izmirly¹, Sara Sahl¹, Amit Saxena², Nathalie Costedoat-Chalumeau³, Jean-Charles Piette⁴, Munther A. Khamashta⁵, Cecilia Pisoni⁶, Deborah Friedman⁷ and Jill P. Buyon¹, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Rheumatology, New York University School of Medicine, New York, NY, ³Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁴Department of Internal Medicine 1., CHU Pitié-Salpêtrière, Paris, France, ⁵Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ⁶Section of Rheumatology and Immunology, Centro de Educación, CEMIC, CABA, Argentina, ⁷Division of Pediatric Cardiology, New York Medical College, Valhalla, NY
Background/Purpose: Life-threatening cardiac manifestations of neonatal lupus (cardiac-NL) include complete block, endocardial fibroelastosis (EFE) and dilated cardiomyopathy (DCM), all supportive of intense fibrosis at the…
Abstract Number: 1651 • 2012 ACR/ARHP Annual Meeting
Higher Corticosteroid Doses Early in Disease Have A Long-Term Influence On Metabolic Syndrome in Systemic Lupus Erythematosus: Data from an International Inception Cohort
Ben Parker¹, Murray B. Urowitz², Dafna D. Gladman³, Mark Lunt⁴, Ian N. Bruce⁵ and Systemic Lupus International Collaborating Clinic (SLICC)⁶, ¹Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁵Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom, ⁶Toronto
Background/Purpose: The Metabolic Syndrome (MetS) is a clustering of metabolic abnormalities associated with an increased risk of developing diabetes and atherosclerosis, and may add to…
Abstract Number: 1656 • 2012 ACR/ARHP Annual Meeting
Treatment of Systemic Necrotizing Vasculitides in Patients ≥65 Years Old: Results of the Multicenter Randomized Cortage Trial
Christian Pagnoux¹, Thomas Quemeneur², Jacques Ninet³, Elodie Perrodeau⁴, Elizabeth Diot⁵, Xavier Kyndt⁶, Benoit de Wazières⁷, jean-Luc Reny⁸, Xavier Puéchal⁹, Pierre-Yves Leberruyer¹⁰, Olivier Lidove¹¹, Philippe Vanhille¹², Pascal Godmer¹³, Aimé Albath-Sadiki¹⁴, Boris Bienvenu¹⁵, Pascal Cohen¹⁶, Luc Mouthon¹⁷, Philippe Ravaud⁴, Loic Guillevin¹⁸ and French Vasculitis Study Group (FVSG)¹⁹, ¹Internal Medicine, Department of Internal Medicine, National Referral Center for Necrotizing Vasculitides and Systemic Sclerosis, Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Université Paris – Descartes, Paris, France, Paris, France, ²Internal medicine, CHR de Valenciennes, Valenciennes, France, ³Department of Nephrology and Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, ⁴Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ⁵Department of Internal Medicine, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France, Tours, France, ⁶Department of Nephrology and Internal Medicine, CH, Valenciennes, Valenciennes, France, ⁷Department of Internal Medicine and Gerontology, Hôpital Universitaire Carémeau, Nîmes, France, Nimes, France, ⁸Service de médecine interne générale Hôpitaux universitaires de Genève, Geneve, Switzerland, ⁹National Referral Center for Rare Systemic Auto-immune Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ¹⁰Hôpital Robert Debré, Centre Hospitalier Universitaire de Reims, Reims, France, Reims, France, ¹¹Médecine interne, Hôpital Croix-Saint-Simon, PARIS, France, ¹²Department of Nephrology and Internal Medicine, Hospital of Valenciennes, Valenciennes, France, Valenciennes, France, ¹³Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, ¹⁴Urc, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, 27 rue du faubourg Saint Jacques, Paris, 75014, France, Paris, France, ¹⁵Médecine interne, CHU Côte de Nacre, CAEN, France, ¹⁶National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹⁷Internal Medicine, Hopital Cochin, Paris, France, ¹⁸Internal Medicine, Cochin University Hospital, Paris, France, ¹⁹Department of Internal Medicine, National Referral Center for Necrotizing Vasculitides and Systemic Sclerosis, Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Université Paris – Descartes, Paris, France
Background/Purpose: To optimize the therapeutic strategy for the elderly with systemic necrotizing vasculitides (SNV; polyarteritis nodosa (PAN), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) or…
Abstract Number: 1139 • 2012 ACR/ARHP Annual Meeting
Inhaled Nitrous Oxide Facilitates Access to Intra-Articular Corticosteroid Injections in Children with Juvenile Idiopathic Arthritis
Mercedes O. Chan¹, Ruth Wyllie² and H. E. Foster³, ¹Department of Pediatrics, Division of Pediatric Rheumatology, University of British Columbia and British Columbia's Children's Hospital, Vancouver, BC, Canada, ²Paediatric Rheumatology, Newcastle Hospitals, NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom, ³Paediatric Rheumatology, Newcastle Hospitals NHS Foundation Trust, Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood affecting 1 in 1000 children. Medical management for arthritis often includes intra-articular…
Abstract Number: 184 • 2012 ACR/ARHP Annual Meeting
The Retrospective Review of 39 Intestinal Behcet’s Disease Focusing On the Requirement for the Immunosuppresive Drugs Other Than Corticosteroid
Yoshitaka Kimura¹, Kurumi Asako², Hirotoshi Kikuchi², Akiteru Takeuchi³ and Hajime Kono², ¹Department of Internal Medicine, Teikyo University school of medecine, Tokyo, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³6-7-8 Arakawa, Tokyo, Japan
Background/Purpose: To examine the demography, clinical characteristics, features of intestinal lesions, treatment, and prognosis in patients with the intestinal Behcet’s disease currently followed at a…
Abstract Number: 98 • 2012 ACR/ARHP Annual Meeting
How to Assess Risks for Pulmonary Infection in Patients Receiving Immunosuppressive Treatment for Rheumatic Diseases? A Report From a Large-Scale Prospective Cohort Study
Hayato Yamazaki¹, Ryoko Sakai¹, Ryuji Koike², Yasunari Miyazaki³, Michi Tanaka¹, Toshihiro Nanki¹, Kaori Watanabe¹, Shinsuke Yasuda⁴, Takashi Kurita⁵, Yuko Kaneko⁶, Yoshiya Tanaka⁷, Yasuhiko Nishioka⁸, Yoshinari Takasaki⁹, Kenji Nagasaka¹⁰, Koichi Amano¹¹, Shigeto Tohma¹², Makoto Dohi¹³, Takahiko Sugihara¹⁴, Haruhito Sugiyama¹⁵, Yasushi Kawaguchi¹⁶, Naohiko Inase¹⁷, Sae Ochi¹⁸, Hiroyuki Hagiyama¹⁹, Nobuyuki Miyasaka²⁰ and Masayoshi Harigai²¹, ¹Department of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ²Clinical Research Center, Tokyo Medical and Dental University, Tokyo, Japan, ³Department of Integrated Pulmonology, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ⁵Department of Medicine II, Hokkaido University, Sapporo, Japan, ⁶Dept of Internal Medicine, Keio Univ School of Medicine, Tokyo, Japan, ⁷The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁸Department of Respiratory Medicine & Rheumotology, The Univeristy of Tokushima Graduate School, Tokushima, Japan, ⁹Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ¹⁰Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, ¹¹Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ¹²Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan, ¹³Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ¹⁴Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ¹⁵Division of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan, ¹⁶Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁷Dept of Integrated Pulmonology, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁸Department of Rheumatology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan, ¹⁹Department of Rheumatology, Yokohama-city Bay Red Cross Hospital, Yokohama, Japan, ²⁰Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, ²¹Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Patients with rheumatic diseases given immunosuppressive therapy are susceptible to various types of infections, especially pulmonary infections that affect their vital prognosis. The aim…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].